Drug Pricing
-
{
- All
- News
- Videos
-
Fake Mounjaro Worth Rs 56 Lakh Seized In Gurugram: What It Can Do To Your Body
Fake Mounjaro injections seized in Gurugram highlight rising counterfeit weight-loss drug risks and severe health dangers.
-
High Cost, Limited Access: How Counterfeit Keytruda Market Puts Cancer Patients At Risk
Keytruda, developed by Merck & Co., belongs to a class of drugs known as immune checkpoint inhibitors, which help the immune system identify and attack cancer cells.
-
Oncologists Explain Why They Prescribe Keytruda To Cancer Patients, When And How It Works
Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
-
What Is Keytruda And Why Is Everyone Talking About It In India's Cancer Fight?
In India, Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
-
Centre Revises Coronary Stent Prices From April 2026: Here's How Much It Should Cost You Now
National Pharmaceutical Pricing Authority revises stent prices, DES capped at Rs 39,186, BMS at Rs 10,762, effective April 2026.
-
Trump Imposes 100% Tariffs On Patented Drugs: Will It Impact India?
The bigger picture threatens a move away from established production hubs like India.
-
Affordable Weight Loss Drugs In India: How Cheap GLP-1s Will Affect Obesity Treatment
Replacing traditional weight management methods with GLP-1 medications can be effective for some, but it's essential to approach this transition with caution.
-
Safety Checks For New Generic Weight-Loss Drugs To Be Increased: Government
New Delhi, March 24 (IANS) Amid serious concerns over recent introduction of multiple generic variants of GLP-1 based weight loss drugs in the Indian market, the government on Tuesday said it has intensified regulatory surveillance against the drug’s
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
Fake Mounjaro Worth Rs 56 Lakh Seized In Gurugram: What It Can Do To Your Body
Fake Mounjaro injections seized in Gurugram highlight rising counterfeit weight-loss drug risks and severe health dangers.
-
High Cost, Limited Access: How Counterfeit Keytruda Market Puts Cancer Patients At Risk
Keytruda, developed by Merck & Co., belongs to a class of drugs known as immune checkpoint inhibitors, which help the immune system identify and attack cancer cells.
-
Oncologists Explain Why They Prescribe Keytruda To Cancer Patients, When And How It Works
Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
-
What Is Keytruda And Why Is Everyone Talking About It In India's Cancer Fight?
In India, Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
-
Centre Revises Coronary Stent Prices From April 2026: Here's How Much It Should Cost You Now
National Pharmaceutical Pricing Authority revises stent prices, DES capped at Rs 39,186, BMS at Rs 10,762, effective April 2026.
-
Trump Imposes 100% Tariffs On Patented Drugs: Will It Impact India?
The bigger picture threatens a move away from established production hubs like India.
-
Affordable Weight Loss Drugs In India: How Cheap GLP-1s Will Affect Obesity Treatment
Replacing traditional weight management methods with GLP-1 medications can be effective for some, but it's essential to approach this transition with caution.
-
Safety Checks For New Generic Weight-Loss Drugs To Be Increased: Government
New Delhi, March 24 (IANS) Amid serious concerns over recent introduction of multiple generic variants of GLP-1 based weight loss drugs in the Indian market, the government on Tuesday said it has intensified regulatory surveillance against the drug’s
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
